News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pulmonary Fibrosis Foundation to Fund Further Therapeutic Evaluation Studies for Compugen Ltd. (CGEN)-Discovered Drug Candidate


10/12/2011 9:30:38 AM

TEL AVIV, Israel & CHICAGO--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) and the Pulmonary Fibrosis Foundation announced today that the Pulmonary Fibrosis Foundation will provide a grant to scientists at the University of Pittsburgh Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease to independently evaluate the therapeutic potential of CGEN-25009 for the treatment of idiopathic pulmonary fibrosis (IPF), a devastating disease with no current effective treatment and which is estimated to affect more than five million people worldwide.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES